hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06272786, orgStudyIdInfo id: 2023-18/128, briefTitle: Suprascapular Nerve Block in Patients Rehabilitated After Arthroscopic Rotator Cuff Repair, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-28, primaryCompletionDateStruct date: 2024-09-01, completionDateStruct date: 2024-10-01, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Kirsehir Ahi Evran Universitesi, class: OTHER, descriptionModule briefSummary: Suprascapular nerve block is an injection method that has been shown to be effective in shoulder rehabilitation in diseases such as adhesive capsulitis and stroke .. Applying the block under USG guidance instead of blinding increases the effectiveness and reduces complications., conditionsModule conditions: Rotator Cuff Tears, conditions: Pain, conditions: Nerve Block, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomised controlled, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Investigator and outcome assessor will be different persons., whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: conventional physiotherapy program., interventions name: Suprascapular nerve block, outcomesModule primaryOutcomes measure: Visual Analog Scale (VAS), primaryOutcomes measure: Visual Analog Scale (VAS), primaryOutcomes measure: Visual Analog Scale (VAS), primaryOutcomes measure: Shoulder joint range of motion (ROM), primaryOutcomes measure: Shoulder joint range of motion (ROM), primaryOutcomes measure: Shoulder joint range of motion (ROM), secondaryOutcomes measure: Shoulder Pain and Disability İndex (SPADİ), secondaryOutcomes measure: Shoulder Pain and Disability İndex (SPADİ), secondaryOutcomes measure: Shoulder Pain and Disability İndex (SPADİ), secondaryOutcomes measure: Modified Constant-Murley Scoring, secondaryOutcomes measure: Modified Constant-Murley Scoring, secondaryOutcomes measure: Modified Constant-Murley Scoring, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ahi Evran University, status: RECRUITING, city: Kirşehir, state: City Centre, zip: 40100, country: Turkey, contacts name: Basak Cigdem Karacay, Assist Prof, role: CONTACT, phone: :+90 386 280 39 00, email: basak.cigdemkaracay@ahivran.edu.tr, contacts name: Basak Cigdem Karacay, Assist Prof, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.14583, lon: 34.16389, hasResults: False
protocolSection identificationModule nctId: NCT06272773, orgStudyIdInfo id: IRAS Ref: 333663, briefTitle: Forced Oscillation and Breathing Pattern in Asthma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Karl Sylvester, class: OTHER, descriptionModule briefSummary: Asthma is a chronic respiratory disease characterised by airway inflammation, bronchoconstriction, and airway hyperresponsiveness. Accurate and reliable assessment of lung function is crucial in diagnosing and monitoring asthma. The forced oscillation technique (FOT) is a non-invasive method that has gained attention in recent years as a valuable tool for evaluating respiratory mechanics in asthma.FOT involves applying small amplitude oscillations at various frequencies to the respiratory system and measuring the resulting pressure and flow responses. These measurements provide valuable insights into the mechanical properties of the airways, including resistance, compliance, and reactance. FOT offers several advantages over traditional spirometry, such as its ability to assess peripheral airway function, sensitivity to small airway abnormalities, and ease of use, particularly in young children or individuals with severe airflow limitation. FOT also allows for assessment of respiratory mechanics in individuals who may struggle with performing spirometry manoeuvres.However, it is unclear whether a change in breathing pattern in patients with obstructive lung disease impacts the assessment of a response to treatment utilising FOT.Several studies have demonstrated a high prevalence of Breathing Pattern Disorders (BPDs) in individuals with asthma. These findings suggest that BPDs may be common in asthma and could contribute to the manifestation and severity of respiratory symptoms. Evidence suggests that BPDs can adversely affect pulmonary function in individuals with asthma. One study demonstrated that children with asthma and dysfunctional breathing exhibited significantly reduced forced expiratory volume in one second (FEV1) compared to asthmatics without BPD. This suggests that abnormal breathing patterns may contribute to airflow limitation in asthma, leading to decreased lung function.We therefore wish to determine the impact of different breathing frequencies on parameters measured using FOT in patients diagnosed with asthma and concomitant obstructive lung function abnormality., conditionsModule conditions: Asthma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 65, type: ESTIMATED, armsInterventionsModule interventions name: Forced Oscillation Test, outcomesModule primaryOutcomes measure: Change in airway resistance at 5 Hertz (Hz) and 19Hz, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06272760, orgStudyIdInfo id: 2024-02-060, briefTitle: Development of a Remote Therapy Protocol for Upper Limb Function Enhancement in Children With Cerebral Palsy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-09-30, completionDateStruct date: 2026-02-28, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Samsung Medical Center, class: OTHER, descriptionModule briefSummary: The perpose of this study: Development and demonstration of a teletherapy protocol to improve upper limb function in children with cerebral palsy., conditionsModule conditions: Cerebral Palsy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized Controlled Trial, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: Single blinding, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Home-based hand-arm bimanual intensive training (Tele-HABIT), interventions name: Hand-arm bimanual intensive training (In-clinic-HABIT), outcomesModule primaryOutcomes measure: Change from Assisting Hand Assessment (AHA) score at post-intervention test (T1-T0)., secondaryOutcomes measure: Change from Baseline Pediatric Motor Activity Log (PMAL) score at post-intervention test (T1-T0)., secondaryOutcomes measure: Change from Baseline Melbourne Assessment 2 (MA2) score at post-intervention test (T1-T0)., secondaryOutcomes measure: Change from Canadian Occupational Performance Measure (COPM) score at post-intervention test (T1-T0)., secondaryOutcomes measure: Change from Pediatric Evaluation of Disability Inventory Computer Adaptive Test (PEDI-CAT) score at post-intervention test (T1-T0)., secondaryOutcomes measure: Change from baseline Magnitude ratio (Accelerometer) at post-intervention test (T1-T0)., secondaryOutcomes measure: Change from baseline Bilateral magnitude(Accelerometer) at post-intervention test (T1-T0)., eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06272747, orgStudyIdInfo id: XH-S003-I-101, briefTitle: A Phase I Study of XH-S003 in Healthy Volunteers, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-22, primaryCompletionDateStruct date: 2024-07-30, completionDateStruct date: 2024-10-30, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: S-Infinity Pharmaceuticals Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: The purpose of the study is to assess the safety, tolerability and pharmacokinetics of XH-S003 in healthy volunteers under SAD (Single ascending dose) and MAD (Multiple ascending dose) studies. In addition, this study evaluates the food effects of XH-S003., conditionsModule conditions: Healthy Adults, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 44, type: ESTIMATED, armsInterventionsModule interventions name: XH-S003, interventions name: Placebo, outcomesModule primaryOutcomes measure: Number of participants with adverse events (AEs), primaryOutcomes measure: Number of participants with adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Beijing Friendship Hospital,Capital Medical University, city: Beijing, country: China, contacts name: Ruihua Dong, MD, role: CONTACT, phone: 010-63139033, email: Ruihua_Dong_RW@163.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06272734, orgStudyIdInfo id: RCV-0007, briefTitle: Reprieve System Pilot Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-23, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-01-31, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Reprieve Cardiovascular, Inc, class: INDUSTRY, descriptionModule briefSummary: The objective of the study is to evaluate the use of the Reprieve System to decongest subjects with acute decompensated heart failure., conditionsModule conditions: Acute Decompensated Heart Failure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Reprieve System, outcomesModule primaryOutcomes measure: Functional Device Success, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tbilisi Heart and Vascular Clinic, status: RECRUITING, city: Tbilisi, zip: 0159, country: Georgia, contacts name: Tamaz Shaburishvili, MD, role: CONTACT, phone: +995 322 479300, email: tamaz_shaburishvili@yahoo.com, geoPoint lat: 41.69411, lon: 44.83368, hasResults: False
protocolSection identificationModule nctId: NCT06272708, orgStudyIdInfo id: IIT-2023-0356, briefTitle: Preliminary Exploration of Thromboelastography in the Monitoring of Anticoagulation in Maintenance Hemodialysis Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-29, primaryCompletionDateStruct date: 2024-02-29, completionDateStruct date: 2024-05-31, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: RenJi Hospital, class: OTHER, descriptionModule briefSummary: Objectives: To investigate the role of thromboelastography parameters (R, K, Angle, MA) in monitoring anticoagulation in maintenance hemodialysis (MHD) patients.Subjects: Two hundred stable MHD patients. Methods: An observational study. Primary outcome: Relationship between thromboelastography parameter R Value and coagulation of hemodialysis circuit and dialyzer.Secondary outcome: Relationship between thromboelastography parameters (K Value, Angle and MA) and coagulation of hemodialysis circuit and dialyzer., conditionsModule conditions: Thromboelastography, conditions: Hemodialysis, conditions: Anticoagulation, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 200, type: ESTIMATED, outcomesModule primaryOutcomes measure: thromboelastography parameter R value, secondaryOutcomes measure: thromboelastography parameter K value, secondaryOutcomes measure: thromboelastography parameter Angle, secondaryOutcomes measure: thromboelastography parameter MA, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Renji Hospital, School of Medicine, Shanghai Jiao Tong University, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200127, country: China, contacts name: Yunyue Guo, role: CONTACT, phone: 0086-021-68383312, email: guoyunyue@renji.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06272682, orgStudyIdInfo id: 6669, briefTitle: Corticosteroids in Carpal Tunnel Syndrome. Prospective Randomised Controlled Non-inferiority Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-17, primaryCompletionDateStruct date: 2024-08-11, completionDateStruct date: 2025-10-11, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Hospital Italiano de Buenos Aires, class: OTHER, descriptionModule briefSummary: The goal of this prospective, randomised, controlled, non-inferiority analytical study is to compare the Boston score in patients treated with systemic (intramuscular) versus local infiltration corticosteroids in mild and moderate carpal tunnel syndrome in patients over 18 years of age with mild or moderate carpal tunnel syndrome.The main questions it aims to answer are:* What is the effectiveness of intramuscular injection of corticosteroids compared to local infiltration in the treatment of mild/moderate carpal tunnel syndrome?* What are the adverse effects and application site pain associated with each route of administration?Patients who meet the inclusion criteria will be asked to participate in the study and sign an informed consent form.The Redcap randomizer will be used to assign the patient to one of the branches.Researchers will compare* Branch A: patients treated with local corticosteroid infiltration in carpal tunnel under ultrasound* Branch B: patients treated with intramuscular corticosteroid injection.Researchers will:* Compare Boston Carpal Tunnel Questionnaire score at 1.5 months, 3 months, 6 months and 12 months post-procedure.* Describe adverse reactions associated with the route of administration.* Compare the pain at the site of application associated with the route of administration., conditionsModule conditions: Carpal Tunnel Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Prospective, randomised, controlled, non-inferiority analytical study, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 106, type: ESTIMATED, armsInterventionsModule interventions name: Systemic bethametasone injection, interventions name: Local bethametasone injection, outcomesModule primaryOutcomes measure: Compare the Boston Carpal Tunnel Syndrome Questionnaire, secondaryOutcomes measure: Adverse reactions, secondaryOutcomes measure: Pain at the site of application, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hospital Italiano de Buenos Aires, status: RECRUITING, city: Buenos Aires, zip: C1199, country: Argentina, contacts name: Jorge Boretto, MD, role: CONTACT, phone: +541169026969, email: jorge.boretto@hospitalitaliano.org.ar, contacts name: Rocio Avanzi, MD, role: CONTACT, phone: +541157727055, email: rocio.avanzi@hospitalitaliano.org.ar, geoPoint lat: -34.61315, lon: -58.37723, hasResults: False
protocolSection identificationModule nctId: NCT06272656, orgStudyIdInfo id: AKR-TACE-001, briefTitle: Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-06-30, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Hebei Medical University Third Hospital, class: OTHER, descriptionModule briefSummary: Primary liver cancer is currently the fourth most common malignant tumor and the second leading cause of tumor mortality in China, posing a serious threat to the lives and health of the Chinese people . At present, non-surgical treatment methods are often used, such as radiofrequency ablation (RFA), Transcatheter arterial chemoembolization (TACE), radiation therapy, and systemic anti-tumor therapy. However, whether it is surgical treatment or non-surgical treatment, commonly used liver cancer related biomarkers in clinical practice during the evaluation of treatment efficacy or regular follow-up of patients include AFP, AFP-L3%, DCP, etc., but there are no reports on whether AKR1B10 can be used for the efficacy evaluation of these treatment methods.Therefore, this project aims to explore the clinical value of AKR1B10 in evaluating the efficacy of liver cancer treatment., conditionsModule conditions: Hepatocellular Carcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: comparison of liver cancer markers AKR1B10, AFP, AFP-L3% and DCP before and after TACE, secondaryOutcomes measure: long-term survival (1-year, 3-year, 5-year), secondaryOutcomes measure: progression- free - time, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: HebeiMUTH, status: RECRUITING, city: Shijia Zhuang, state: Hebei, zip: 050000, country: China, contacts name: Yuemin Nan, role: CONTACT, phone: +8633188602489, email: Hb20231221@163.com, contacts name: Pei Guo, role: CONTACT, phone: 17835683894, email: G545632518@163.com, geoPoint lat: 34.17775, lon: 109.84894, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_ICF, hasProtocol: True, hasSap: False, hasIcf: True, label: Study Protocol and Informed Consent Form, date: 2023-12-25, uploadDate: 2024-02-02T21:48, filename: Prot_ICF_000.pdf, size: 258859, hasResults: False
protocolSection identificationModule nctId: NCT06272630, orgStudyIdInfo id: DW_DWJ1464401, briefTitle: Study to Evaluate the Efficacy and Safety of DWJ1464 in Patients With Chronic Liver Disease, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2023-02-06, primaryCompletionDateStruct date: 2024-05-31, completionDateStruct date: 2024-08-31, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Daewoong Pharmaceutical Co. LTD., class: INDUSTRY, descriptionModule briefSummary: This study aims to assess the effect of DWJ1464 on improvement of liver function in patients with Chronic liver disease. Patients with Chronic liver disease aged 19 years or over will participate in the study. The study design is a multi-center double-blinded randomized placebo-controlled trial. The patients were diagnosed with Chronic liver disease based on our criteria and were randomized to either the placebo or DWJ1464 administration group. Primary endpoint was the change of ALT level after 8 weeks compared to the baseline. Secondary endpoints included the change of ALT level after 4 weeks, the change rate of ALT level after 8 weeks and improvement of fatigue, compared to the baseline. the adverse effect of DWJ1464 were also recorded., conditionsModule conditions: Chronic Liver Disease, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 258, type: ESTIMATED, armsInterventionsModule interventions name: DWJ1464, interventions name: Placebo of DWJ1464, outcomesModule primaryOutcomes measure: At 8 weeks, the change of ALT level compared to baseline, secondaryOutcomes measure: At 4 weeks, the change of ALT level compared to baseline, secondaryOutcomes measure: At 4, 8 weeks, the change of AST level compared to baseline, secondaryOutcomes measure: At 4, 8 weeks, the change of liver function comparator GGT level compared to baseline, secondaryOutcomes measure: At 8 weeks, the change of liver function comparator Fibrotest compared to baseline, secondaryOutcomes measure: At 8 weeks, the change of liver function comparator Fibroscan compared to baseline, secondaryOutcomes measure: At 4, 8 weeks, the change of K-CFQ(Korean version of Chalder Fatigue Scale) scores, compared to the baseline, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: SoonChunHyang University Seoul Hospital, city: Seoul, zip: 04401, country: Korea, Republic of, geoPoint lat: 37.566, lon: 126.9784, hasResults: False